Results Highlights:- Revenue and net profit reached US$78.9 million and US$18.8 million, respectively.- APAC market revenue grew significantly by 31.0%, driven by both organic growth and contributions from SJ Medicare and PT Revass, the South Korean and Indonesian distributors acquired in Q4 2023.- Total sales volume of proprietary products remained at 717,000 units.- In 1H2024, the Group made extensive efforts to integrate eucatech AG, a German company acquired last year, into its operations and reorganize its production lines, and expects eucatech AG to resume production and shipment in Q3.- The Group has been actively registering products of eucatech AG in various countries and regions, and eucaLimus, a coronary drug eluting stent, has already received registration approval in Malaysia.- For the clinical studies of TricValve, patient enrollment has commenced in 13 hospitals in the PRC. In Japan, the Group is working closely with the Pharmaceuticals and Medical Devices Agency (“PMDA”) and the US Food and Drug Administration (“FDA”) to prepare for the clinical trial and registration process.- In May 2024, the Group engaged the main contractor for its largest R&D and manufacturing facility in Hangzhou, which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million product units upon commencement of production.- The Group’s financial position remained strong, as evidenced by the cash and bank balances of US$246.7 million as of June 30, 2024.- The Group expects to maintain a stable dividend policy, demonstrating its confidence in future prospects.HONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its interim results for the six months ended June 30, 2024 (the “Reporting Period”), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “The global economy has been highly volatile in recent years, as a result of factors such as geopolitical tensions and major central banks shifting their monetary policies. Albeit the challenging external environment, we were able to seize the opportunity to implement a series of measures to enhance operational efficiency and integrate the businesses of SJ Medicare, PT Revass and eucatech AG acquired last year into our Group. We believe the investments made in the first half year are crucial to supporting our future sustainable growth.”For the Reporting Period, the Group’s revenue decreased slightly by 3.1% to US$78.9 million, mainly attributable to decline in sales volume in the US due to integration of Cardiovascular Systems, Inc. (“CSI”) into Abbott Laboratories (“Abbott”), and in the PRC market due to on-going impact of anti-corruption campaign, as well as the Group’s termination of distribution of certain third-party products, despite the significant sales growth recorded in APAC, as well as the modest revenue growth in Japan in terms of Japanese Yen. Excluding the impact of the foreign exchange fluctuations, total revenue would have recorded a slight year-on-year increase of 0.6%. Gross profit amounted to US$55.8 million while gross profit margin stood at 70.7%.Despite the decline in revenue and the short-term increase in expenses incurred by the Group’s series of measures to enhance operational efficiency and integrate the businesses acquired in the previous year, the Group maintained a healthy level of net profit for the first half of 2024. It is worth noting that, excluding the operating expenses of the newly acquired businesses, the three core operating expenses, namely selling and distribution expenses, general and administrative expenses and research and development expenses, for the first half of 2024, remained flat against the same period last year. As of June 30, 2024, the Group maintained a strong financial position with cash and bank balances of approximately US$246.7 million, laying a solid foundation to support its growth objective.Robust Balloon Sales in APAC and EMEAThe Group’s proprietary balloon products continued to gain traction worldwide. In the first half of 2024, revenue from the APAC market saw organic growth of a marked 8.6% year-on-year, thanks to strong balloon sales growth in markets such as Malaysia, Hong Kong, India, Vietnam and Singapore. Particularly, the latest generation of scoring balloon, Scoreflex TRIO, recorded a rapid rise in sales since it was launched in Malaysia in early 2024. Together with the additional contribution of US$4.3 million from the SJ Medicare and PT Revass, distributors acquired in South Korea and Indonesia respectively in Q4 2023, the revenue generated from APAC amounted to a total of US$24.0 million, representing a significant increase of 31.0% year-on-year.In addition, mainly attributable to the increase in sales of the Group’s proprietary balloon products in direct sales markets such as Germany, France and Spain, as well as distributor sales markets including Czech Republic and Slovakia, revenue generated from EMEA slightly increased by 1.3% to US$19.2 million, even being partly offset by the termination of distribution agreement with CSI for atherectomy products.During the first half of 2024, Scoreflex TRIO continued to drive revenue generated from Japan, the Group’s largest single-country market, in terms of Japanese Yen, achieving an 8.1% increase year-on-year.Integrating Newly Acquired Business to Drive Future GrowthFollowing the acquisition of eucatech AG in November 2023, extensive efforts were made to integrate eucatech AG into the Group’s operation and reorganize production lines. The Group has been actively registering eucatech AG’s four products, namely eucaLimus, Support C, Resistant, and VITUS, in various countries and regions to avail those products via the Group’s own sales network to physicians and patients in different markets. In the first half of 2024, eucaLimus was granted registration approval in Malaysia, one of the Group’s direct sales markets. Registration applications for eucatech AG’s products have also been submitted to relevant regulatory bodies in Hong Kong, Malaysia, Switzerland, Italy and Saudi Arabia and are pending approval. The Group also promoted eucatech AG’s products at major conferences including EuroPCR, as well as educated distributors about these offerings so that sales could be ramped up smoothly once the products become available.In April 2024, the Group supported eucatech AG’s on-site Medical Device Directive (“MDD”) and Medical Device Regulation (“MDR”) surveillance audit, as such, was able to extend the CE Mark expiration dates for their 4 products under the MDD framework. All these efforts are expected to see eucatech AG resume production and shipment in the third quarter of the year.Relentless Drive to Translate Innovations into Thriving Product LinesAs of June 30, 2024, OrbusNeich had an aggregate of over 50 approved products. The Group has maintained a steadfast commitment to translating its R&D efforts into commercially successful products. To date, the Group achieved major milestones, including:- Obtaining NMPA approval for Teleport Neuro, FDA approval for Teleport XT and JADE PLUS 14/18/35 OTW, CE Mark for Sapphire ULTRA and Sapphire NC ULTRA;- Submission of registration applications to the NMPA for its Guiding Catheter;- Completion of the clinical trial patient enrollment for Scoreflex TRIO in the PRC, with the NMPA application expected to be submitted in Q3 2024;- Preparation for the Sapphire 3 clinical trial in the US, with enrollment scheduled to begin in Q3 2024.Alongside these regulatory and commercialization efforts, the Group continued to invest in new pipeline products, such as the Corepass modular microcatheter, support catheter and the JADE Plus. Registration applications for these innovative offerings are planned for submission to various authorities in 2024.Meanwhile, the joint venture OrbusNeich P&F made significant efforts to advance the clinical studies of TricValve in two major Asia Pacific markets. Patient enrollment has commenced in the PRC for its clinical trial, and the clinical trial and registration process in Japan is being prepared in close collaboration with the PMDA and the FDA.Boosting Production Capacity through Rigorous Quality Processes and Operational ExcellenceThe Group has always prioritized product quality, which is ensured by a robust quality management system. During the Reporting Period, various sites successfully passed audits conducted by various regulatory and notifying bodies. Furthermore, the Group remains committed to enhancing operational efficiency and reducing production costs by continually optimizing manufacturing processes, work-in-progress inventory levels, and employee productivity. To meet future production needs, the Group will construct its largest R&D and manufacturing facility in Hangzhou, the PRC, for which it engaged the main contractor in May 2024 and which is expected to begin operation in 2027, adding an annual production capacity of 2.4 million units of products upon commencement of production.Mr. Chien concluded: “Looking ahead, as new sales strategies are being executed in the PRC and the US markets, we expect these key geographies will regain growth momentum in second half of the year. Meanwhile, OrbusNeich has maintained active efforts to expand our market presence. On the product front, we are leveraging our comprehensive sales network and brand recognition to market innovative endovascular intervention products to enhance the solutions we provide to the physicians. New products from eucatech AG which is expected to resume production soon will also contribute to improved profitability. We are also actively identifying M&A opportunities that align with our strategic priorities and position us for sustainable growth. Despite the first-half headwinds, we remain optimistic about restoring growth momentum soon and expect to maintain a stable dividend policy for shareholders based on our robust financial position.”- End -About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As of June 30, 2024, OrbusNeich has more than 230 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/. Copyright 2024 ACN Newswire via SeaPRwire.com.

业绩亮点：- 收入及纯利分别达78.9百万美元及18.8百万美元。- 亚太地区市场收入显著增长31.0%，主要受惠于内部增长，以及于2023年第四季收购的韩国分销商SJ Medicare及印尼分销商PT Revass所带来的贡献。- 自有产品的总销量维持在717,000件。- 于2024年上半年，集团将去年收购的德国公司eucatech AG与集团的营运整合，并重组其生产线，预期eucatech AG将于第三季度恢复生产及出货。- 集团一直积极在多个国家及地区注册eucatech AG的产品，其中，冠状动脉药物洗脱支架eucaLimus已于马来西亚获批准注册。- TricValve的临床研究方面，OrbusNeich P&F已为该产品于中国13家医院展开病人入组。在日本，集团正与医药品医疗机器综合机构（「PMDA」）及美国食品药品监督管理局（「FDA」）紧密合作，为该产品的临床测试及注册程序作准备。- 于2024年5月，集团已为旗下位于杭州的最大研发及生产设施委聘总承建商，预期于2027年投产，届时将为集团的年产能增加240万件产品。- 于2024年6月30日，集团的财务状况稳健，现金及银行结余达246.7百万美元。- 集团预期维持稳定的股息政策，显示对前景充满信心。香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司（「业聚医疗」或「集团」；股份代号：6929）今天宣布截至2024年6月30日止六个月(「报告期」)的中期业绩。尽管面对不同的市场挑战，集团的收入及本公司拥有人应占期内利润仍分别保持于78.9百万美元及18.8百万美元的水平。业聚医疗董事长、执行董事兼行政总裁钱永勋先生表示：「由于地缘政治局势紧张及主要央行货币政策转变等因素，全球经济近年一直非常动荡。尽管外围环境充满挑战，我们仍能把握契机，采取一系列措施提高营运效率，并将去年收购的SJ Medicare、PT Revass 及eucatech AG与集团的业务整合。我们相信，上半年所作的投资对于支持集团未来可持续增长至关重要。」报告期内，尽管亚太地区的销售录得大幅增长，以及日本市场以日圆计价收入也达到温和增长，然而，由于Abbott Laboratories（「雅培」）对Cardiovascular Systems, Inc. (「CSI」)进行整合令美国销量下跌、中国市场受到反腐运动持续影响，以及集团终止分销若干第三方产品，集团的收入微跌3.1%至78.9百万美元。若撇除外汇波动影响，总收入按年微升0.6%。毛利为55.8百万美元，毛利率达70.7%。尽管收入下降，以及集团为提高营运效率及整合去年收购的业务而采取了一系列措施，导致短期开支增加，但2024年上半年的纯利仍维持稳健。值得一提的是，若撇除新收购业务的营运开支，2024年上半年的销售及分销开支、一般及行政开支及研发开支三项核心营运开支的水平，事实上与去年同期相若。截至2024年6月30日，集团的财务状况稳健，现金及银行结余达约246.7百万美元，为支持集团达致增长目标奠定坚实基础。亚太地区及欧洲、中东及非洲地区球囊销售表现强劲集团的自有球囊产品继续深受全球欢迎。2024年上半年，有赖马来西亚、香港、印度、越南及新加坡等市场的球囊销售额增长强劲，带动亚太地区市场收入取得8.6%的自然增长。特别是最新一代刻痕球囊Scoreflex TRIO，自2024年初在马来西亚推出以来，销量迅速攀升。这加上集团在2023年第四季收购的韩国分销商SJ Medicare及印尼分销商PT Revass在期内带来4.3百万美元的额外收入贡献，推动亚太地区的总收入同比大升31.0%至24.0百万美元。此外，主要受惠于集团的自有球囊产品在直销市场，如德国、法国及西班牙，以及分销市场，如捷克及斯洛伐克的销量有所增加，即使集团与CSI终止有关旋磨产品的分销协议抵销了部分收入升幅，来自欧洲、中东及非洲的收入仍增加1.3%至19.2百万美元。2024年上半年，Scoreflex TRIO继续推动集团最大单一地域市场――日本的收入增长，按日圆计价，较去年同比增长8.1%。整合新收购业务　推动未来增长继2023年11月收购eucatech AG后，集团积极投入各项工作，致力将eucatech AG整合至集团营运，并重组其生产线。集团积极在多个国家及地区注册eucatech AG旗下eucaLimus、Support C、Resistant及VITUS四款产品，以便透过集团自身的销售网络，向不同市场的医生及患者提供这些产品。2024年上半年，eucaLimus于集团的直销市场马来西亚获批准注册，而eucatech AG其他产品的注册申请亦已提交予香港、马来西亚、瑞士、意大利及沙特阿拉伯的相关监管机构，正等待批准。此外，为稳步提升eucatech AG旗下产品上市后的销量，集团于EuroPCR等重要会议上进行推广，并向分销商提供有关产品的资讯。2024年4月，集团为eucatech AG接受关于医疗器械指令（「MDD」）及医疗器械条例（「MDR」）现场监督审核提供支援，从而在MDD框架下延长上述四款产品的CE标志到期日。通过以上举措，eucatech AG有望于今年第三季恢复生产及出货。致力将创新理念转化为丰富的产品线截至2024年6月30日，业聚医疗共有逾50款获批产品。集团一直坚持将研发成果转化为成功商业化的产品，至今已实现多个重大里程碑，包括：- Teleport Neuro获得NMPA批准；Teleport XT、JADE PLUS 14/18/35 OTW获FDA批准；Sapphire ULTRA及Sapphire NC ULTRA取得CE标志；- 向国家药监局提交导引导管注册申请；- Scoreflex TRIO在中国的临床测试病人入组完成，预计将于2024年第三季向国家药监局提交申请；- 现正为Sapphire 3美国临床测试做准备，并计划于2024年第三季在美国开始进行病人入组。除上述监管及商业化工作外，集团亦继续投资于新产品管线，例如Corepass模组化微导管、支撑导管及JADE Plus，并预计于2024年向各监管机构提交该三种创新产品的注册申请。与此同时，合资企业OrbusNeich P&F于两个主要亚太区市场大力推进TricValve临床研究。在中国，临床测试已展开病人入组；而在日本，OrbusNeich P&F与PMDA及FDA紧密合作，准备于日本进行TricValve临床测试及注册。透过严格质量控制及卓越运营流程提升产能集团重视产品质量，并以严格的质量管理系统把关。报告期内，集团多个生产基地顺利通过了不同监管机构及认证机构的审核。此外，集团亦持续优化生产流程、半成品库存及人员的生产力，以提升营运效率及降低生产成本。为满足未来生产所需，集团于中国杭州市兴建旗下最大的研发生产设施，并已于2024年5月委聘总承建商，预期于2027年投产，届时将为集团的年产能增加240万件产品。钱先生总结道：「展望未来，我们预期集团在中国及美国两大主要地域市场实施新销售策略后，此两大巿场将能在今年下半年重拾增长动力。与此同时，我们亦会继续拓展市场据点。产品方面，我们会利用完善的销售网络及品牌知名度，推广创新的血管介入产品， 致力为医生提供更佳的解决方案。而随着eucatech AG即将恢复生产，其新增至集团的产品亦有助加强我们的盈利能力。我们亦正积极物色符合集团策略重点的并购机会，以进一步推动集团可持续增长。尽管上半年面临诸多挑战，我们仍对迅速恢复增长势头保持乐观，并期望在稳健的财务基础上，为股东维持稳定的股息政策。」— 完 —关于业聚医疗集团控股有限公司业聚医疗是一家主要的全球医疗器械制造商，专门生产用于经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）的介入器械。业聚医疗的总部位于中国香港，产品销往全球超过70个国家和地区。集团亦积极将业务扩展至神经血管介入及结构性心脏病领域。截至2024年6月30日，业聚医疗已于全球拥有超过230项授权专利及已公布专利申请，其内部研发团队拥有逾20年的产品开发经验，并已开发出世界领先的专有技术。如需了解更多详情，请访问集团官网：https://orbusneich.com/ Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 2024年8月15日，康哲药业发布2024年中期业绩公告，整体营业额和期间利润环比去年下半年稳步提升。2024年上半年实现营收36.11亿元，同比下降21.7%，环比增长6.1%；若全按药品销售收入计算营收42.88亿元，同比下降22.6%，环比增长8.9%；其中，非国采独家产品及创新产品合计销售收入为人民币24.05亿元，占全按药品销售收入计算营业额的56.1%。实现净利润9.03亿元，同比下降52.8%，环比大幅增长92.8%。2024年，正值康哲药业创新产品商业化的开局之年，也是国家带量采购（国采）对其业绩影响得以释放的关键节点。因黛力新进入第七批国采目录，于2022年11月执行；波依定和优思弗进入第八批国采目录，于2023年7月开始执行；且三款原研药品均未中标，对公司经营业绩带来负面影响。2024年上半年，公司整体业绩环比去年下半年呈现增长态势，标志着康哲药业已基本消化国采影响，成功迈入由非国采独家产品和创新产品驱动业务增长的“新产品时代”。随着莱芙兰（亚甲蓝肠溶缓释片）于今年6月获批上市，美泰彤（甲氨蝶呤注射液）增加成人活动性类风湿关节炎适应症于7月获批上市，康哲药业处于商业化阶段的创新药组合已扩充至5款产品（含6项适应症），并有丰富的差异化创新管线储备。聚创新之能，乘发展之势，康哲药业正以更健康的产品结构全面塑造发展新动能，进一步迎接高质量发展新周期。“合作+自主”双擎研发模式驱动管线量质齐升，加速创新科研成果转化深厚的创新药研发管线是康哲药业长期发展的重要驱动力。公司以坚持满足临床未尽之需，解决患者用药之困为创新目的，以“合作研发+自主研发”双擎驱动，不断布局FIC（全球首创）与BIC（同类最佳）创新产品，并提升研究与临床开发的能力与效率，实现医药科研成果社会和商业价值的快速转化。截至目前，康哲药业中国获批上市的创新产品组合已扩充至5款产品（含6项适应症），其中4款创新药（维图可、益路取、美泰彤-银屑病适应症、维福瑞）已获纳入国家医保目录，并进入规模化临床应用；并新增创新药莱芙兰、美泰彤（类风湿关节炎）在中国获批上市。康哲药业亦稳步推进创新产品临床开发相关工作。目前，德昔度司他片正处于中国NDA审评中；合计约10个项目即将开展/正在推进以注册性随机对照试验（RCT）为主的临床试验。同时，公司不断强化基础研究和自主创新能力，目前已顺利推进10余项自主研究项目，其中三款创新药（VEGFA+ANG2四价双特异性抗体、高选择性TYK2抑制剂CMS-D001片、及GnRH受体拮抗剂CMS-D002胶囊）已进入临床开发阶段。此外，公司创新管线不断扩充。今年3月，康哲药业与Incyte再度达成合作，获得选择性小分子口服JAK1抑制剂povorcitinib在中国大陆、香港、澳门、台湾地区及东南亚11国等国家/地区的研究、开发、注册及商业化产品的独家许可权利，进一步丰富公司在白癜风和其他免疫介导皮肤病治疗领域的产品组合。接下来，康哲药业每年将持续以更高效率、更可控成本源源不断产出创新产品，加速创新价值释放，通过以非国采独家产品和创新产品为主导的健康产品结构，迎接高质量、可持续的业绩增长。成功的商业化体系，高效协同创新产品临床价值释放深耕专科领域32年，成功的商业化能力是康哲药业核心竞争力之一。通过持续强化与整合“开放式商业化平台”，已实现心脑血管/消化、皮肤、眼科三大独立运营业务深入发展，并在关联领域扩张边界；已建立强执行力、高素质的专业推广团队、广泛的渠道与资源覆盖，为公司创新产品实现快速市场准入与品牌塑造奠定了坚实基础。康哲药业四款已进入大规模临床应用的创新药，覆盖中枢神经、皮肤、肾内、消化系统等相关疾病领域，与原有品种在团队和渠道等方面协同增效发展。同时，凭借已获纳入国家医保目录的契机，公司正大力推动医院开发、品牌力建设，真实世界研究，及围绕医学驱动的学术推广工作；并结合患者援助及科普教育项目，提升患者对创新药可及性，推动创新产品临床价值释放。皮肤医美业务“康哲美丽”以皮肤治疗处方产品为核心，轻医美产品和皮肤学级护肤品为延展，不断完善皮肤治疗、皮肤护理和医疗美容全生命周期皮肤健康管理平台。在皮肤处方药临床开发方面，已完成磷酸芦可替尼乳膏白癜风适应症的关键真实世界研究，正在推进中国大陆注册上市申请工作。同时，持续补充再生类轻医美产品矩阵，其中童颜针的中国医疗器械注册申请已于报告期内获受理；并新获三款处于中国注册性临床阶段的再生类轻医美产品，“少女针”、“微晶瓷”、及脱细胞基质植入剂的中国商业化独占许可权利。业绩公告显示，截至6月底，康哲药业推广网络覆盖中国超5.5万家医院及医疗机构，约28万家终端零售药店。通过在心脑血管、消化、中枢神经系统、肾内科、眼科、皮肤科等专科领域优势积累，康哲药业稳步释放专科业务规模效益，高筑业务竞争壁垒，持续构建自身优势专科治疗领域护城河，为多款创新产品和独家品种的商业化带来广阔前景。擘画国际化布局，为增量市场蓄势聚力东南亚业务公司“康联达健康”整合集团化优势资源，将康哲药业在中国市场的成功经验、全球优质产品和创新技术资源外溢共享到东南亚，加速完善东南亚业务“研产销”一体化的开放式平台，为中国和全球药企高质量“出海”战略赋能，也为康哲药业打开更大的增量发展空间。截至6月底，康联达健康已建立有竞争力的产品组合，拥有十余款差异化品种，覆盖肿瘤、中枢神经、自免、皮肤科、眼科等疾病领域。康联达健康正加速推进多款创新储备产品在东南亚各国的上市申请和注册相关工作，如芦可替尼乳膏、亚甲蓝肠溶缓释片、地西泮鼻喷雾剂等；并与君实生物正共同推动特瑞普利单抗（抗PD-1单抗）于东南亚多国的注册进程，以期尽快惠及当地肿瘤患者。去年12月，康哲药业、康联达健康携手康龙化成等共同促成了新加坡生产工厂的收购。今年，各方正持续有序推进该生产工厂的设备检测、质量核查、生产质量体系认证等系列工作，旨在加速CDMO业务进程，并进一步优化集团海外供应链和生产能力。此布局将助力康哲药业未来与全球合作伙伴开展更多产业间合作，共同构建共赢互惠的开放式医疗创新生态。结语自1992年创立至今，康哲药业顺延行业发展脉络，以前瞻性视野成功推动了三次意义重大的战略转型。公司起步于进口原研药品的代理，逐步发展至控制原研/独家成熟产品权利，再到实现了全面创新转型，每一步都踏在产业发展迭代的节奏中。征程万里风正劲，康哲药业目标如炬，不断垒筑发展厚度，构建穿越周期的韧性。如今，随着国采对公司业绩的影响逐步释放，康哲药业已焕然一新，在拥抱阶段性创新成果的同时，以更充分的准备去迎接未来更长远、更健康的发展。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化业务竞争力，并将皮肤医美、眼科业务独立运营，培育专科小领域的大龙头，提升专科规模效率。同时业务版图拓展至东南亚市场，着力成为全球药企进军东南亚市场的“桥头堡”，助力康哲药业高质量持续健康发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及本集团的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。本集团并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，本集团对该等第三方声明及预测不承担责任。 Copyright 2024 亚太商讯 via SeaPRwire.com.

BRISBANE, AUS, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO FSI ANZ 2024 invites cybersecurity professionals in the Financial Services Industry to join this free virtual event designed to inspire and share intelligence. The online gathering will cover everything from cyber strategy, risk management, governance, program and incident management, leadership, to enabling business growth.CISO FSI ANZ offers a unique opportunity to expand your knowledge and find ways to avoid cyber threats in the FSI industry. Benchmark your strategies with peers and learn how to get buy-in and collaboration in your projects across the board.Key topics include:Strategies to advance your company’s cyber security maturity modelsHow to align cyber risk management with the company's goalsComplying with APRA regulations in Australia and MBIE in New ZealandThe impacts of the privacy act reform in information securitySuccessful practices to mitigate the increase of third-party risksBridging the talent gap by investing in culture, education and trainingNavigating the “AI high” by leveraging its benefits while minimising its risksCISO FSI ANZ is an essential online event for those looking to advance their knowledge and network within the cybersecurity community. Join us on 12 September 2024 at 10 AM AEDT or 12 PM NZT.It’s free! Register now: https://bit.ly/4dpyOUYVisit website: https://ciso-fsi-anz.coriniumintelligence.com/About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

CANBERA, AUSTRALIA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - CISO Canberra invites cyber security professionals to explore the critical role of public sector cyber security in protecting the public and driving transformative leadership strategies for delivering the 2023-2030 Australian Cyber Security Strategy.The tech demo exhibition will showcase cutting-edge services and innovations driving change in the cybersecurity landscape. InfoSec leaders will share their strategic insights in no-nonsense talks, providing valuable substance over empty rhetoric.Key themes include:STRENGTH IN UNITY: Building robust shields against cyber threats by navigating the 2023-2030 Australian Cyber Security Strategy to be the most secured nation.AWARENESS, EMPOWERMENT, & COORDINATION: Maturing cyber security culture through collective responsibility and collaborative efforts for enhanced resilience.PROACTIVE GRC MANAGEMENT: Integrating Zero Trust and evaluating risks in supply chains, data and AI to empower decision making at the pace of innovation.MODERNISING THREAT DETECTION & RESPONSE: Embracing cutting-edge technologies and strategies to advance security, integrity and resilience capabilities.CISO Canberra 2024 is an essential event for those looking to advance their knowledge and network within the cybersecurity community. Join us at the Canberra Rex Hotel on 14 November 2024 for an event that promises to inspire and empower.Use the code ACNNEWS20 for 20% off the ticket price.Register here: https://bit.ly/4dqzPfbVisit website: https://ciso-bris.coriniumintelligence.com/ About Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.Media Contact:Claudia Peixoto, Marketing Managerclaudia.peixoto@coriniumgroup.com Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. In the case that all medicines were directly sold by the Company, the turnover was RMB4,287.5 million, representing a decrease of 22.6% compared with 1H 2023, an increase of 8.9% compared with 2H 2023; Among which, the total revenue of non-National VBP exclusive products and innovative products was RMB2,404.7 million, accounting for 56.1% of CMS’s revenue in the case that all medicines were directly sold by the Company. Profit for the period was RMB903.4 million, representing a decrease of 52.8% compared with 1H 2023, a substantial increase of 92.8% compared with 2H 2023.The year 2024, not only marks the first year of the commercialization of CMS’s innovative products, but also a crucial point for the release of National Volume Based Procurement (“National VBP”) impact on its financial performance. Deanxit entered the seventh batch of National VBP in November 2022, Plendil and Ursofalk entered the eighth batch of National VBP in July 2023, and none of the three original drugs were selected, which had a negative impact on the Company’s business performance. In 1H 2024, the Company’s overall performance showed a growth trend compared with 2H 2023, indicating that CMS has basically digested the impact of National VBP and successfully entered the "New Product Era" where non-national VBP exclusive products and innovative products drive its growth.With the approval for marketing of LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) in June and METOJECT (Methotrexate Injection)’s additional indication of active rheumatoid arthritis (RA) in adults in July this year, CMS's innovative drug portfolio in the commercialization stage has expanded into 5 products (including 6 indications); simultaneously with a rich and differentiated innovative pipeline reserve. Gathering the power of innovation and riding the momentum of development, CMS is comprehensively shaping new drivers for development with a healthier product structure, further opening up a new cycle of quality development.The "Collaborative and In-house" dual-engine R&D model drives the simultaneous improvement in quantity and quality of the pipeline, accelerating the transformation of innovative biotechnologyA profound innovative drug R&D pipeline is an important driving force for the long-term development of CMS. The Company adheres to the purpose of innovation for meeting the unmet clinical needs and solving the difficulties of patient medication, and promotes innovation development through a two-wheel drive of “Collaborative R&D and In-house R&D”, continuously deploying FIC (first-in-class) and BIC (best-in-class) innovative products, and enhancing the capabilities and efficiency of research and clinical development to achieve a rapid transformation of scientific outcomes into social and commercial values.As of now, CMS's innovative product portfolio approved for marketing in China has been expanded into 5 products (including 6 indications), among which, 4 innovative drugs (VALTOCO, ILUMETRI, METOJECT - psoriasis indication, VELPHORO) have been included in the National Reimbursement Drug List (NRDL) and entered large-scale clinical application; also, CMS newly added LUMEBLUE and METOJECT (RA), for being approved for marketing in China recently.CMS has also steadily advanced the clinical development of innovative products. Currently, Desidustat Tablets is under NDA review in China; Also, a total of about 10 projects have been prepared/launched for their registrational clinical trials, mainly randomized controlled trials (RCT).At the same time, the Company had continued to strengthen basic research and independent innovation capabilities, and successfully promoted more than 10 in-house R&D projects, among which, three innovative drugs (VEGFA/ANG2 Tetravalent Bispecific Antibody, Highly Selective TYK2 Inhibitor CMS-D001 Tablets, and GnRH Receptor Antagonist CMS-D002 Capsules) have entered the clinical development stage.In addition, the Company’s innovative pipeline has continued to expand. CMS Skinhealth collaborated with Incyte once again, and has obtained exclusive license to research, develop, register and commercialize povorcitinib, a selective oral small-molecule JAK1 inhibitor, in countries/territories including Mainland China, Hong Kong, Macau, Taiwan Region and 11 Southeast Asian countries. This further enriched the product portfolio of CMS Skinhealth in the treatment of vitiligo and other immune-mediated dermatology diseases.Subsequently, CMS will continue to produce innovative products with higher efficiency and more controllable costs every year, accelerating the release of innovative value and embracing quality and sustainable performance growth through a healthy product structure dominated by non-National VBP exclusive products and innovative products.Successful commercialization system releases the clinical value of innovative products in an efficient and collaborative mannerAfter 32 years of deep cultivation in specialty therapeutical fields, successful commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, it has achieved in-depth development of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology, and ophthalmology, and expanded its boundaries in related fields. Additionally, the Company established a highly qualified, professional promotion team with strong execution, as well as extensive channel and resource coverage, which has laid a solid foundation for the rapid market entry and brand building of its innovative products.Four innovative drugs of CMS have entered large-scale clinical applications, covering various disease fields such as central nervous system, dermatology, nephrology, and gastroenterology, and developed synergistically with the existing marketed products in promotion team and channels. Meanwhile, leveraging on the opportunity of being included in the NRDL, CMS is advancing hospital development, brand building, real world studies and medically-driven academic promotion. CMS is improving patients’ accessibility to innovative drugs with the help of patient aid and disease knowledge popularization programs, promoting the release of products’ clinical value.The Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to light medical aesthetic products and dermatology-grade skincare products, continuously improving the construction of a full life-cycle skin-health management platform covering dermatological treatment, skincare, and medical aesthetics through internal development and external collaboration. In terms of clinical development of dermatology prescription drugs, CMS has completed the Pivotal Real World Study for ruxolibinib cream in vitiligo, and is advancing the registration application process in Mainland China. At the same time, it has continuously complemented the regenerative light medical aesthetic portfolio, among which the China’s medical device registration application of the Poly-L-lactic Acid Microparticle Filler Injection has been accepted by the NMPA during the Reporting Period; and the Company has newly obtained exclusive licenses of three regenerative light medical aesthetic products (Polycaprolactone Microsphere Gel for Injection, Calcium Hydroxylapatite Microsphere Gel for Injection, and Decellularized Extracellular Matrix Implant), which are currently under the registrational clinical trial stage in China.The results announcement shows that, as of the end of June, the promotion network of CMS has covered over 55,000 hospitals and medical institutions, and approximately 280 thousand retail pharmacies in China.Leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, nephrology, ophthalmology, dermatology and other specialty therapeutical fields, CMS steadily releases the scale effect of its specialty businesses, and builds high competition barriers, creating broad commercial potential for its innovative products and exclusive products.Drawing up the internationalization layout to gather momentum for the incremental marketIntegrating the advantageous resources of the Company, its Southeast Asia business “Rxilient Health”, shares and expands the successful experience of CMS gained from the China market, as well as global quality products and innovative technological resources, into the Southeast Asia market. This accelerates the improvement of the platform integrating “R&D, manufacture, and commercialization” of the Southeast Asia business, empowering Chinese and global pharmaceutical companies to implement the “overseas development” strategy, and also opening up a larger space for incremental development opportunities for CMS.As of the end of June, Rxilient Health has established a competitive product portfolio with more than ten differentiated products, covering therapeutic areas such as oncology, central nervous system, autoimmune, dermatology, and ophthalmology, etc. Rxilient Health is accelerating the relevant work on the market registration processes in Southeast Asian countries for innovative pipeline products, such as ruxolitinib cream, Methylthioninium Chloride Enteric-coated Sustained-release Tablets, and Diazepam Nasal Spray, etc. Furthermore, Rxilient Health collaborated with Junshi Biosciences to promote the registration process of toripalimab (anti-PD-1 monoclonal antibody) in multiple countries in Southeast Asia, aiming to benefit local cancer patients as soon as possible.In December last year, the Company and Rxilient Health joined hands with Pharmaron and other partners to complete the purchase of the Singapore manufacturing plant. This year, all relevant parties have been orderly advancing a series of work for the Singapore manufacturing plant, including equipment testing, quality verification, and production quality system certification, etc., so as to accelerate the CDMO business development, and to optimize the Company’s overseas supply chain and manufacturing capabilities. The business layout will further facilitate more inter-industry cooperation between CMS and global partners in the future, thus jointly building a win-win medical innovation ecosystem with mutual benefits.ConclusionSince its establishment in 1992, CMS has followed the development pattern of the industry and has promoted three significant strategic transformations successfully with a forward-looking vision. The Company started as an agent of imported original drugs, gradually developed to control the rights of original/exclusive products, and then achieved a comprehensive innovative transformation. Each step of the transformation is in sync with the industry development trends. CMS steadily aims towards the ultimate goal, and constantly builds up its strength and resilience to persist through the industry development cycle. With the gradual release of the impact of national VBP on its financial performance, CMS has been transforming into a brand-new company. While embracing the innovation achievements in each stage, CMS is fully prepared for a sustainable and healthier development in the future.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

FINANCIAL HIGHLIGHTS- In the first half of the year, the Group recorded the following operating results:  – Revenue rose by 2.3% to RMB14,345 million; gross profit margin rose by 1.6 percentage points to 50.4%  – Net operating cash inflow increased by 40.6% to RMB2,730 million  – Net profit attributable to equity holders of the Company was RMB1,952 million with net profit margin of 13.6%, and EBITDA margin was 24.0%- Working capital remained at a healthy level:  – The percentage of gross average working capital to revenue was 7.1%  – The cash conversion cycle was 31 days, representing an increase of 1 day as compared to the same period last year- The Board resolved to declare an interim dividend of RMB37.75 cents per ordinary share of the Company issued or to be issued upon conversion of convertible securities for the six months ended 30 June 2024.OPERATIONAL HIGHLIGHTS- The retail sell-through for the overall platform decreased by low-single-digit, including online and offline channels- Channel inventory increased by mid-single-digit comparing to the same period last year. The inventory turnover and ageing structure remained at a healthy level- Offline channel new product sell-through decreased by mid-single-digitHONG KONG, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - Li Ning Company Limited (stock codes: 2331 (HKD counter) and 82331 (RMB counter)) announces today its 2024 interim results for the six months ended 30 June 2024.Financial ResultsIn the first half of 2024, China’s economy demonstrated an orderly recovery, with favorable national policies continuously injecting vitality into the market. Against the backdrop of the rising public health awareness, numerous international and national events have spurred public’s enthusiasm for sports. Currently, overall consumer confidence still has room for recovery, and the market is in a gradual and positive adjustment phase.Leveraging the brand’s professional sports background, the Group maximizes its insights into the sports industry, understanding of sports categories, and technological innovation capabilities, concentrating on five core categories of running, basketball, fitness, badminton, and sports casual during the Reporting Period. Through continuous research and development (“R&D”) investment and technological innovation, the Group consistently enhances product capabilities, optimizes consumer experience, and ensures sustainable development in the long run while expanding the Group’s business.In the first half of 2024, the Group’s overall performance remained stable with pragmatic growth. During the Reporting Period, revenue amounted to RMB14,345 million, representing an increase of 2.3% as compared to the corresponding period of 2023 (2023 H1: RMB14,019 million). Gross profit increased by 5.8% from RMB 6,839 million in the same period of 2023 to RMB 7,236 million, and the overall gross profit margin was 50.4% (2023 H1:48.8%), the gross profit margin increased by 1.6 percentage points as compared to the corresponding period of last year. Basic earnings per share was RMB75.80 cents (2023 H1: RMB80.63 cents). The Board resolved to declare an interim dividend of RMB37.75 cents (2023 H1: RMB36.20 cents) per ordinary share of the Company issued or to be issued upon conversion of convertible securities for the six months ended 30 June 2024. The interim dividend payout ratio is 50%.In terms of cash flow management, the Group's net cash generated from operating activities during the Reporting Period amounted to RMB2,730 million (2023 H1: RMB1,942 million). As at 30 June 2024, cash and cash equivalents (including cash at banks and in hand, and fixed term deposits with original maturity of no more than three months) amounted to RMB6,147 million, representing a net increase of RMB703 million, as compared with the position as at 31 December 2023. Adding back the amount recorded as fixed-term deposits held at banks, cash balance amounted to RMB17,558 million, which represented a net decrease of RMB417 million as compared to 31 December 2023. During the period, revenue increased year-on-year while the efficiency of settlement remained stable, which, in conjunction with the reasonable purchase and payment plan, contributed to the year-on-year increase in net cash generated from operating activities. The Group will continue to place extra emphasis on its cash flow management to ensure stable development of the Group in the long run.Operational SummaryDuring the Reporting Period, the Group adhered to the core strategy of “Single Brand, Multi-categories, Diversified Channels” focusing on seven major business transformation tracks and continuously strengthening its sports genes to establish a clear professional sports brand positioning. Meanwhile, the Group was efficiently empowered in supply chain management, logistics platform, channel expansion and store upgrading, jointly building a solid foundation for the overall sales of the Group.In terms of technological innovation, in May 2024, the Group successfully held a technology conference with the theme of “In My Name, Tech LI-NING” , which demonstrated that the Group has built two key pillars of product development and innovation consisting of technology R&D and sports science research through long-term accumulation of technological innovation. At the conference, the Group presented its six innovative technologies of “Carbon Core” , “Dual-Stage Assist Curves”, “Super Jiang” , “GCU”, “Super BOOM” and “Extreme Boom Fiber” , and also unveiled three new innovations for the first time: the running shoes of “Shadow 3”, the premium racing shoes of “Dragonflight” and dual-vent nanotechnology for rainstorm protection.In terms of professional products and marketing, the Group continued to focus on the five core categories of running, basketball, badminton, fitness and sports casual, and continued to make efforts in the innovation in sports technology. At the same time, the Group also actively integrated with sports fashion culture, launched sports products with both technology and fashion attributes and continuously enhanced the core competitiveness of products. In addition, the Group actively deployed universal marketing to enhance consumers’ awareness of the Group’s products, continuously enhance brand influence and expand its consumer base.In the midst of a great year for sports, the Group launched a campaign theme “In My Name” , to encourage everyone to engage in sports activities and create their own highlight moments. Through delivering the brand proposition and spirit and telling stories of the athletes from the national gold medal team, top athletes in various categories and sports KOLs, as well as overall demonstrating Li Ning’s technological strength, launching theme series products and creating atmosphere for themes at stores, the Group reinforces the professional brand image of LI-NING, realizes the whole chain from brand proposition to product experience, and deeply connects the brand with each consumer.In terms of supply chain management, the Group constructed an all-round and high-efficiency supply chain ecosystem. It not only deeply explored and expanded high-quality supplier resources for high-end sports and outdoor products to form a strong supplier matrix, but also flexibly responded to market changes with a flexible supply strategy as the core.In terms of logistics management, the Group adopted refined logistics plan management, customized strategies based on the characteristics of the business divisions, and optimized the process of goods warehousing and delivery. Meanwhile, the logistics informationization platform empowered distributors to share information in real time, improved the efficiency of store distribution, and further improved the quality of logistics services.In terms of channel expansion and image upgrading, the Group actively optimized its channel layout, consolidated and expanded its competitive advantage in the high-end market by closing low-efficiency stores and strengthening the renovation and expansion of premium stores. Meanwhile, the active development of emerging markets, the new upgrading of the 9th generation stores, and the successful establishment of premium outlets further enhanced the brand image and market influence. In order to create an immersive experience of key events, 4,238 stores introduced key visual display designs featuring “In My Name” themes and core sports resources in the first half of the year, further enhancing consumers’ visual experience and brand awareness.As of 30 June 2024, the number of conventional stores, flagship stores, China LI-NING stores, LI-NING 1990 stores, factory outlets and brand stores under LI-NING brand (including LI-NING Core Brand and LI-NING YOUNG) amounted to 7,677, representing a net increase of 9 Point-of-sale (“POS”) as compared to 31 December 2023. The number of distributors was 44 (including sales channels of China LI-NING stores), representing a net decrease of 2 as compared to 31 December 2023, demonstrating the Group’s precision and efficiency in channel layout.In terms of retail operation, in the first half of the year, the Group deepened the innovation and practice of the single-store operating model to effectively promote the comprehensive implementation of retail operation standards. The store management efficiency has been significantly improved through the comprehensive promotion of its retail end sales planning system and the implementation of the system in core stores.In terms of new retail business, the Group strengthened community operations and content creation through digital transformation to achieve efficient conversion of private traffic, effectively improving sales and conversion efficiency. In addition, the Group actively explored diversified business models, including attracting traffic through social platforms such as Douyin and online business cooperation with core channels, constantly injecting new momentum into store sales, increasing the proportion of out-of-store sales in stores, and further enhancing the operating efficiency of stores.In respect of the e-commerce operation, the e-commerce of Li Ning continued to focus on breakthroughs in professional functional products, especially achieving rapid growth in the field of running shoes, while professional basketball shoe products also consolidated its market leading position. In addition, in terms of online exclusive IP, the Group has successfully created a number of IP that have gained volume and reputation in the industry. During the period, the Group achieved synergistic growth of e-commerce business and retail operation through effective integration and innovative practices across online and offline channels, driving a significant increase in sales performance and further strengthening of market share.In terms of kidswear business, LI-NING YOUNG comprehensively streamlined the youth product matrix, clarified the core competitiveness of clothing and accessories, and improved the footwear product matrix. For marketing, LI-NING YOUNG consolidated its marketing resources and actively explored omni-channel marketing and community operation. By actively cooperating with basketball star Wade to further increase the brand influence. LI-NING YOUNG also actively actively carried out various member community activities and launched new celebrity athlete in-store opening activities to continuously drive store traffic. As at 30 June 2024, the total number of LI-NING YOUNG POS in China amounted to 1,438, representing a net increase of 33 POS since the end of the previous quarter and a net increase of 10 POS since the beginning of this year. The Group will continue to intensely develop its LI-NING YOUNG business, take a product focused approach to upgrade core product technology and design, advance the exploration of market demands and product categorization and strengthen brand promotion, so as to develop LI-NING YOUNG into a leading professional sportswear brand for kids in China.OutlookThe Group will continue to practice its core strategy of “Single Brand, Multi-categories, Diversified Channels”, persistently strengthen its product capabilities and integrate its operational resources to propel the Group towards stable and enduring growth by leveraging the organizational capability as an efficient corporation:– Develop the fundamental business with stability. The Group will continue to amplify the market influence of the LI-NING brand, focusing on the development of its five core categories including running, basketball, fitness, badminton and sports casual. Through investment in research, development and innovation, the Group will achieve continuous upgrading of its product matrix to meet the growing consumer demand for high-quality and personalized sports equipment, thereby reinforcing and expanding the Group’s market leading position in core areas.– Optimize and upgrade the product structure. The Group will further upgrade its diversified product matrix under the single-brand strategy, aligning with the evolving market trends and consumer preferences. By fully leveraging the complementary functions of “China LI-NING” and “LI-NING 1990” in the sports casual sector, and expanding multiple dressing scenarios, the Group will enhance the competitiveness of its brands in diverse scenarios.– Look to the future and seize opportunities to make a breakthrough. The Group will actively explore breakthroughs and take the lead in entering new tracks in sports consumption. By tapping into the huge potential of the women’s, outdoor and youth markets, formulating targeted marketing strategies and launching products that meet the needs of the target groups, the Group aims to make breakthroughs in these new areas.– Optimize market expansion strategy. To achieve comprehensive market coverage, the Group will optimize the allocation of resources to existing high-level markets to improve market efficiency. Concurrently, by actively exploring emerging markets and formulating strategies for overseas markets, the Group strives to achieve significant breakthroughs in overseas markets while keeping a steady and sustainable momentum.Mr. Li Ning, Executive Chairman and Joint CEO of the Group, concluded, “The country's series of in-depth market reform policies will steadily advance, providing the Group with a fair and more vibrant market environment, and opening up broader growth space. The Group will adhere to its established development strategy, rely on the professional sports genes of its brands and continue to launch high-quality sporting products for the public. At the same time, the Group will continue to cultivate the sports market in China, and ride the wave of the Olympics, upholding the spirit of ‘Anything is Possible’, to propel the Chinese sports industry onto the international stage.”- END -About the GroupLi Ning Company Limited is one of the leading sports brand companies in China, mainly operating professional and leisure footwear, apparel, equipment and accessories under the LI-NING brand. Headquartered in Beijing, the Group has brand marketing, research and development, design, manufacturing, distribution and retail capabilities. It has established an extensive retail distribution network and supply chain management system in China. The Group is committed to be the most prominent, stylish, world-leading sports brand from China.In addition to its core LI-NING brand, the Group also manufactures, develops, markets, distributes, sells various sports products which are selfowned by or licensed to the Group, including Double Happiness (table tennis), AIGLE (outdoor sports), Danskin (fashionable fitness products for dance and yoga) and Kason (badminton), which are operated through joint venture/associate with third parties of the Group. Copyright 2024 ACN Newswire via SeaPRwire.com.

MANILA, Aug 16, 2024 - (ACN Newswire via SeaPRwire.com) - Darwinbox, a global leader in providing end-to-end Human Resources Management Systems (HRMS), has significantly transformed the operations of Security Bank Corporation, one of the largest private domestic universal banks in the Philippines and its subsidiaries.This comes as Darwinbox continues to enhance the HR landscape in the Philippines by helping companies optimize their human resources (HR) and improve overall operational efficiency.Security Bank EVP and Chief People Officer, Nerissa Berba, said that Darwinbox, a new-age, enterprise-ready Human Capital Management (HCM) platform, optimized the bank's processes, reduced manual tasks, and enhanced efficiency with streamlined workflows.Security Bank has already observed significant enhancements in its HR processes thanks to Darwinbox. To date, it has automated close to 90 per cent of HR processes, leading to a 67 per cent increase in HR operational efficiency within the first year, which exceeded the initial projection of 30 per cent. Consequently, this has allowed for a 30 per cent improvement in report generation speed and a 75 per cent reduction in the time taken for performance administration ensuring full compliance with policies.Berba further said that Darwinbox met all the bank’s HCM requirements. First, the entire employee lifecycle, from hire-to-retire, can be managed within Darwinbox, allowing the bank to have one system for all its employees’ needs. The Bank has implemented most of the Darwinbox modules, ensuring a consistent experience across the majority of the organization and HR processes.Additionally, the simplicity and user-friendliness of the Darwinbox interface, along with its deep functionality and intuitive mobile app, add significant value to the Bank’s operations. The no-code backend of the highly configurable platform empowers its HR team to tailor processes to the organization’s needs without external consultants.“[Darwinbox] is truly an empowering platform for an enterprise that is customer-first and people-empowered,” Berba said.Security Bank currently provides banking services across the Philippines through a dedicated workforce of nearly 9,000, who deliver the brand’s promise of ‘BetterBanking’.“Our commitment to a future-ready organization hinged on a compelling employee value proposition and a transformative work culture,” Berba said.Meanwhile, Darwinbox, founded in Asia and currently catering to over 950 enterprises worldwide, is actively expanding its presence in the Philippines.The company plans to engage various sectors, utilizing its advanced HR technology to address the diverse needs of organizations in the region. This expansion is in line with Darwinbox's goal to provide businesses with comprehensive and intuitive HR solutions, specifically designed for the unique challenges and opportunities within the Philippine market.Media Contact:Shruti Parmarshruti@bloomingdalepr.comBloomingdale Public Relations Copyright 2024 ACN Newswire via SeaPRwire.com.

财务业绩摘要- 上半年，集团录得以下经营成果：  – 收入上升2.3%至143.45亿元人民币；毛利率上升1.6个百分点至50.4%  – 经营现金净流入上升40.6%至27.30亿元人民币  – 本公司权益持有人应占净溢利为19.52亿元人民币，净利率为13.6%，息税前利润加折旧及摊销率为24.0%- 运营资金保持健康水平：  – 平均运营资金总额占收入比为7.1%  – 现金循环周期为31天，比去年同期增加1天- 董事会决议宣派截至2024年6月30日止六个月之中期股息每股已发行或于可换股证券转换后将予发行的本公司普通股37.75分人民币经营业绩摘要- 整体零售流水（包括线上及线下）录得低单位数下降- 渠道库存同比上升中单位数，库存周转与库龄结构保持在健康水平- 新品线下零售流水录得中单位数下降香港, 2024年8月16日 - (亚太商讯 via SeaPRwire.com) – 李宁有限公司（香港联交所股份代号：2331（港币柜台）及82331（人民币柜台））今天宣布集团截至2024年6月30日止六个月之中期业绩。财务业绩2024年上半年，中国经济展现出有序的复苏态势，国家政策利好持续为市场注入活力。国民健康意识不断提升大背景，伴随多项国际性及国家级体育赛事的到来，催化了民众运动热情。目前，整体消费信心仍具恢复空间，市场正在逐步良性调整中。期内，集团依托品牌的专业运动基因，充分发挥运动行业洞察力、运动品类理解力及科技创新研发力，专注于跑步、篮球、健身、羽毛球和运动生活五大核心品类。通过持续的研发投入和科技创新，不断推动产品力的升级，优化消费者体验，确保集团在保持业务扩展的同时，实现长期可持续的发展。2024年上半年，集团整体业绩平稳，务实发展。期内，集团收入达143.45亿元人民币，较2023年同期上升2.3%（2023年上半年：140.19亿元人民币）。毛利较2023年同期的68.39亿元人民币上升5.8%至72.36亿元人民币，集团整体毛利率为50.4%，较去年同期上升1.6个百分点（2023年上半年：48.8%）。每股基本收益为75.80分人民币（2023年上半年：80.63分人民币）。董事会决议宣派截至2024年6月30日止六个月之中期股息，每股已发行或于可换股证券转换后将予发行的本公司普通股37.75分人民币（2023年上半年：36.20分人民币），中期派息比率为50%。现金流管理方面，期内经营活动产生之现金净额为27.30亿元人民币（2023年上半年：19.42亿元人民币）。于2024年6月30日之现金及等同现金项目（包括银行现金及手头现金，以及原到期日不超过三个月的定期存款）为61.47亿元人民币，较2023年12月31日净增加7.03亿元人民币。加回被记录在银行定期存款中的金额，现金余额为175.58亿元人民币，较2023年12月31日净减少4.17亿元人民币。期内，收入同比增长，回款效率保持稳定，同时集团合理安排采购及付款计划，促成经营活动产生之现金净额同比上升，集团将持续以现金流管理作为重点工作，以保证公司长期稳定的发展。经营概要期内，集团秉持「单品牌、多品类、多渠道」的核心战略，聚焦七大业务变革赛道，持续强化运动基因，明确品牌专业运动定位，并在供应链管理、物流平台、渠道拓展以及门店升级方面高效赋能，共同构筑了集团整体销售的坚实基础。在科技创新方面，2024年5月，集团成功举办「以我为名，科技李宁」主题科技大会，展现集团在长期科技创新积累之下，形成的科技研发及运动科学研究两大产品研发创新支柱，并展示集团的六大创新科技：「碳核芯」、「最速曲线系统」、「超级弜」、「GCU」、「超级䨻」、「极限䨻丝」，同时亦首次发布三大创新成果：「绝影3」跑鞋、顶级竞速跑鞋「龙雀」、防暴雨双透纳米科技。专业产品与营销方面，集团继续专注于跑步、篮球、羽毛球、健身和运动生活五大核心品类，持续在运动科技创新方面发力，同时亦积极与运动潮流文化接轨，推出兼具科技与时尚属性的运动产品，不断增强产品的核心竞争力。此外，集团积极布局全域营销，加强消费者对集团产品的认知，不断提升品牌影响力，扩大消费者基础。体育大年背景下，集团推出「以我为名」主题活动，鼓励每个人成为运动主角，从传递品牌主张和精神，到国家金牌队运动员、多品类顶级运动员及运动KOL的运动者故事，再到李宁科技实力的整体展现、主题系列产品推出、终端主题氛围打造，夯实李宁品牌的专业形象，实现从品牌主张到产品体验的全链路，深度连接品牌与每一个消费者。供应链管理方面，集团构建了全方位、高效能的供应链生态体系，不仅深度挖掘并扩充了高端运动与户外产品的优质供应商资源，形成强大的供应商矩阵，更以柔性供应策略为核心，灵活应对市场变化。物流管理方面，集团采用精细化物流计划管理，根据事业部特点定制策略，优化货品入仓与发货流程。同时，物流信息化平台赋能经销商，实时共享信息，提高门店配货效率，物流服务的质量进一步提升。渠道拓展与形象升级方面，集团积极优化渠道布局，通过关闭低效店铺并强化优质店铺的改造与拓展，巩固并扩大在高层级市场的竞争优势。同时，新兴市场的积极开拓，九代店铺的全新升级，以及超级奥莱的成功打造，均进一步提升品牌形象与市场影响力。为了营造沉浸式的关键赛事体验，上半年已有4,238家门店引入「以我为名」主题活动和核心运动资源的关键视觉陈列设计，进一步增强消费者的视觉感受和品牌认知。截至2024年6月30日，李宁牌（包含李宁核心品牌及李宁YOUNG）常规店、旗舰店、中国李宁时尚店、LI-NING 1990店、工厂店、品牌集合店的销售点数量为7,677家，较2023年12月31日净增加9家；经销商44家（包括中国李宁时尚店渠道），较2023年12月31日净减少2家，展现集团在渠道布局上的精准和高效。在零售运营方面，上半年集团深化单店经营模式的创新与实践，有效推动零售运营标准的全面落地。通过终端门店销售计划系统的全面推进与核心门店的系统落地，实现门店管理效率的显著提升。在新零售业务方面，集团通过数字化转型，强化社群运营和内容创造，实现私域流量的高效转化，销售额与转换效率均实现有效提升。此外，集团积极探索多元化商业模式，包括通过抖音等社交平台引流及与核心渠道的线上业务合作，不断为终端销售注入新动力，提升门店的离店销售占比，进一步增强门店经营效率。在电商运营方面，李宁电商继续专注于专业功能类产品的突破，尤其在跑步鞋领域实现快速增长，专业实战篮球鞋产品亦巩固了市场领先地位；此外，在线上专供单品领域，集团成功打造多款在业界获得体量与口碑的单品。期内，集团通过线上线下渠道的有效整合与创新实践，实现电商业务与零售运营的协同增长，推动销售业绩的显著提升和市场份额的进一步加强。童装业务方面，李宁YOUNG对青少年产品矩阵进行深入梳理，明确服装和配饰的核心竞争力，完善鞋类产品矩阵。营销方面，李宁YOUNG整合市场营销资源，积极探索全渠道营销及社群运营，并通过与篮球明星韦德合作，提升品牌影响力；积极开展各类会员社群活动、打造全新的运动明星进店开业活动，助力门店引流。截至2024年6月30日，于中国，李宁YOUNG销售点数量共计1,438个，较上一季末净增加33个，本年迄今净增加10个。集团将继续深入发展李宁YOUNG业务，聚焦产品，提升产品核心科技与设计，深耕市场需求及品类规划，同时强化品牌推广，推动李宁YOUNG成为中国儿童首选的专业运动童装品牌。前景展望集团将继续践行「单品牌、多品类、多渠道」的核心战略，不断强化产品力，并通过整合营运资源，务求以高效的企业组织能力，推动集团实现稳健且持续的增长：– 基本面业务稳健发展：集团将持续深化李宁品牌的市场影响力，重点发展跑步、篮球、健身、羽毛球和运动生活五大核心品类。通过研发创新投入，实现产品矩阵的持续升级，以满足消费者对高质量、个性化运动装备日益增长的需求，巩固并扩大集团在核心领域的市场领导地位；– 产品结构优化升级：集团将进一步升级单品牌战略下多元化的产品矩阵，顺应市场趋势和消费者偏好的演变，充分发挥「中国李宁」及「LI-NING 1990」在运动生活领域的补充作用，拓展多元的穿搭场景，增强品牌在多元场景下的竞争力；– 放眼未来择机破局：集团将积极探索破局，率先切入体育消费新赛道，挖掘女子、户外和青少年市场的巨大潜力，制定针对性的营销策略，推出符合目标群体需求的产品，力求在这些新领域取得突破；– 优化市场拓展策略：为了实现全面的市场覆盖，集团将优化现有高层级市场的资源分配，提高市场效率。同时，积极开拓新兴市场，并制定针对海外市场的策略，力求在保持稳健步伐的同时，海外市场可实现破局。集团执行主席兼联席行政总裁李宁先生总结：「国家一系列深化市场改革政策扎实推进将为集团提供公平且更有活力的市场环境、开辟更为广阔成长空间。集团将恪守既定的发展战略，依托品牌的专业运动基因，持续为大众推出优质的体育用品。与此同时，集团将继续深耕中国市场，并乘奥运东风，秉持『一切皆有可能』的精神，推动中国体育产业走向国际舞台。」- 完 -关于李宁有限公司李宁有限公司是中国领先的体育品牌企业之一，以经营李宁品牌专业及休闲运动鞋、服装、器材和配件产品为主。集团总部位于北京，拥有品牌营销、研发、设计、制造、经销及零售能力，目前已于中国建立庞大的零售分销网络以及供应链管理体系。集团致力于成为源自中国并被世界认可的、具有时尚性的国际一流专业运动品牌企业。除核心品牌李宁牌外，集团亦生产、开发、推广、分销、销售多个自有、特许或与集团第三方设立的合资╱联营企业经营的其他品牌体育产品，包括红双喜乒乓球产品、AIGLE（艾高）户外运动用品、Danskin舞蹈和瑜伽时尚健身产品及Kason（凯胜）羽毛球产品。 Copyright 2024 亚太商讯 via SeaPRwire.com.